Taken together, thse data show that pitavastatin and simvastatin are able to inhibit Rab11b activity, leading to decreased recycling of integrin β1, and ultimately suppressing the ability of breast cancer cells to successfully engage the brain metastatic ECM. The gene discussed is RAB11B; the disease is breast carcinoma.